{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:58:06Z","timestamp":1780059486674,"version":"3.54.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,23]]},"DOI":"10.7759\/cureus.105739","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:51:51Z","timestamp":1774331511000},"source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint Inhibitor Overlap Syndrome: Myocarditis, Myositis, and Myasthenia Gravis in a Patient With Metastatic Melanoma"],"prefix":"10.7759","author":[{"given":"Samuel","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Harish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad","family":"Althumairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Mysore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31100473","article-title":"Managing select immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"31","author":"Cheema PK","year":"2024","unstructured":"Cheema PK, Iafolla MA, Abdel-Qadir H, et al.. Managing select immune-related adverse events in patients treated with immune checkpoint inhibitors. Curr Oncol. 2024, 31:6356-83. 10.3390\/curroncol31100473","journal-title":"Curr Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.80015","article-title":"Immune checkpoint inhibitor-related myositis and associated triad overlap syndrome","author":"Rubino S","year":"2026","unstructured":"Rubino S, Cannon GW, Sauer BC, et al.. Immune checkpoint inhibitor-related myositis and associated triad overlap syndrome. Arthritis Care Res. 2026, 10.1002\/acr.80015","journal-title":"Arthritis Care Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103011","article-title":"Immune checkpoint inhibitor-related neurotoxicity: incidence and management. A systematic review and meta-analysis","volume":"140","author":"Nielsen DL","year":"2025","unstructured":"Nielsen DL, Juhl CB, Chen IM, Wang Y, Nielsen OH, Santomasso BD. Immune checkpoint inhibitor-related neurotoxicity: incidence and management. A systematic review and meta-analysis. Cancer Treat Rev. 2025, 140:103011. 10.1016\/j.ctrv.2025.103011","journal-title":"Cancer Treat Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00252","article-title":"Risk of knowledge gaps among nononcologists caring for patients with cancer: the example of immune checkpoint inhibitors","volume":"20","author":"Bourne G","year":"2024","unstructured":"Bourne G, Das D, Jacobson JO, Sadeghi N. Risk of knowledge gaps among nononcologists caring for patients with cancer: the example of immune checkpoint inhibitors. JCO Oncol Pract. 2024, 20:1331-5. 10.1200\/OP.24.00252","journal-title":"JCO Oncol Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7064","article-title":"Physician awareness of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Khalid AB","year":"2022","unstructured":"Khalid AB, Calderon G, Jalal SI, Durm GA. Physician awareness of immune-related adverse events of immune checkpoint inhibitors. J Natl Compr Canc Netw. 2022, 20:1316-20. 10.6004\/jnccn.2022.7064","journal-title":"J Natl Compr Canc Netw"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe DN","year":"2024","unstructured":"Lipe DN, Qdaisat A, Krishnamani PP, et al.. Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel). 2024, 14:1794. 10.3390\/diagnostics14161794","journal-title":"Diagnostics (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/5399073","article-title":"Immunotherapy-induced overlap syndrome: myositis, myasthenia gravis, and myocarditis-a case series","volume":"2024","author":"Aggarwal N","year":"2024","unstructured":"Aggarwal N, Bianchini D, Parkar R, Turner J. Immunotherapy-induced overlap syndrome: myositis, myasthenia gravis, and myocarditis-a case series. Case Rep Med. 2024, 2024:5399073. 10.1155\/2024\/5399073","journal-title":"Case Rep Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al.. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018, 71:1755-64. 10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas N","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020, 9:e013757. 10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem JE","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, et al.. Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023, 13:1100-15. 10.1158\/2159-8290.CD-22-1180","journal-title":"Cancer Discov"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2025.104188","article-title":"Myocarditis, myositis, and myasthenia gravis: the complexities of treating steroid-refractory triple M syndrome","volume":"30","author":"Halloran S","year":"2025","unstructured":"Halloran S, Patel R, Tilkens B, et al.. Myocarditis, myositis, and myasthenia gravis: the complexities of treating steroid-refractory triple M syndrome. JACC Case Rep. 2025, 30:104188. 10.1016\/j.jaccas.2025.104188","journal-title":"JACC Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/457285-immune-checkpoint-inhibitor-overlap-syndrome-myocarditis-myositis-and-myasthenia-gravis-in-a-patient-with-metastatic-melanoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:51:51Z","timestamp":1774331511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/457285-immune-checkpoint-inhibitor-overlap-syndrome-myocarditis-myositis-and-myasthenia-gravis-in-a-patient-with-metastatic-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.105739","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}